
Vinod Tiwari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6458841/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors. Journal of Biomolecular Structure and Dynamics, 2022, 40, 3609-3625.	3.5	25
2	Natural Products and some Semi-synthetic Analogues as Potential TRPV1 Ligands for Attenuating Neuropathic Pain. Current Pharmaceutical Biotechnology, 2022, 23, 766-786.	1.6	12
3	Immune-microbiome interplay and its implications in neurodegenerative disorders. Metabolic Brain Disease, 2022, 37, 17-37.	2.9	5
4	Structure-based virtual screening and molecular dynamics simulation for the identification of sphingosine kinase-2 inhibitors as potential analgesics. Journal of Biomolecular Structure and Dynamics, 2022, 40, 12472-12490.	3.5	8
5	Unlocking the potential of TRPV1 based siRNA therapeutics for the treatment of chemotherapy-induced neuropathic pain. Life Sciences, 2022, 288, 120187.	4.3	25
6	Recent advancements in biomarker research in schizophrenia: mapping the road from bench to bedside. Metabolic Brain Disease, 2022, 37, 2197-2211.	2.9	5
7	Modulation of KIF17/NR2B crosstalk by tozasertib attenuates inflammatory pain in rats. Inflammopharmacology, 2022, 30, 549-563.	3.9	15
8	Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones. Bioorganic and Medicinal Chemistry, 2022, 60, 116698.	3.0	6
9	Inhibition of pan-Aurora kinase attenuates evoked and ongoing pain in nerve injured rats via regulating KIF17-NR2B mediated signaling. International Immunopharmacology, 2022, 106, 108622.	3.8	15
10	Decrypting the cellular and molecular intricacies associated with COVID-19-induced chronic pain. Metabolic Brain Disease, 2022, 37, 2629-2642.	2.9	4
11	A network map of endothelin mediated signaling pathway. Journal of Cell Communication and Signaling, 2021, 15, 277-282.	3.4	15
12	Current and emerging roles of Cockayne syndrome group B (CSB) protein. Nucleic Acids Research, 2021, 49, 2418-2434.	14.5	30
13	Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies. Current Topics in Medicinal Chemistry, 2021, 21, 547-570.	2.1	14
14	Attenuation of ongoing neuropathic pain by peripheral acting opioid involves activation of central dopaminergic neurocircuitry. Neuroscience Letters, 2021, 754, 135751.	2.1	17
15	Tozasertib Attenuates Neuropathic Pain by Interfering with Aurora Kinase and KIF11 Mediated Nociception. ACS Chemical Neuroscience, 2021, 12, 1948-1960.	3.5	19
16	Promising traditional Indian medicinal plants for the management of novel Coronavirus disease: A systematic review. Phytotherapy Research, 2021, 35, 4456-4484.	5.8	33
17	LEO1 is a partner for Cockayne syndrome protein B (CSB) in response to transcription-blocking DNA damage. Nucleic Acids Research, 2021, 49, 6331-6346.	14.5	8
18	A comprehensive review on pharmacology of efflux pumps and their inhibitors in antibiotic resistance. European Journal of Pharmacology, 2021, 903, 174151.	3.5	30

#	Article	IF	CITATIONS
19	Kinesin Nanomotors Mediated Trafficking of NMDA-Loaded Cargo as A Novel Target in Chronic Pain. ACS Chemical Neuroscience, 2021, 12, 2956-2963.	3.5	10
20	Epigallocatechin-3-gallate improves chronic alcohol-induced cognitive dysfunction in rats by interfering with neuro-inflammatory, cell death and oxido-nitrosative cascade. Metabolic Brain Disease, 2021, 36, 2141-2153.	2.9	13
21	ADMET Profiling in Drug Discovery and Development: Perspectives of In Silico, In Vitro and Integrated Approaches. Current Drug Metabolism, 2021, 22, 503-522.	1.2	37
22	Multifarious Targets and Recent Developments in the Therapeutics for the Management of Bone Cancer Pain. ACS Chemical Neuroscience, 2021, 12, 4195-4208.	3.5	14
23	A brain proteomic signature of incipient Alzheimer's disease in young <i>APOE</i> ε4 carriers identifies novel drug targets. Science Advances, 2021, 7, eabi8178.	10.3	23
24	Emerging role of nanomedicine in the treatment of neuropathic pain. Journal of Drug Targeting, 2020, 28, 11-22.	4.4	9
25	Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice. Biochimie, 2020, 168, 198-209.	2.6	28
26	Activation of µ-δ opioid receptor heteromers inhibits neuropathic pain behavior in rodents. Pain, 2020, 161, 842-855.	4.2	43
27	Adenosine receptor signalling: Probing the potential pathways for the ministration of neuropathic pain. European Journal of Pharmacology, 2020, 889, 173619.	3.5	12
28	Sitagliptin mitigates oxidative stress and up-regulates mitochondrial biogenesis markers in Brown adipose tissues of high-fat diet fed obese mice through AMPK phosphorylation. Obesity Medicine, 2020, 19, 100265.	0.9	4
29	Cockayne syndrome proteins CSA and CSB maintain mitochondrial homeostasis through NAD ⁺ signaling. Aging Cell, 2020, 19, e13268.	6.7	26
30	Underpinning the Neurobiological Intricacies Associated with Opioid Tolerance. ACS Chemical Neuroscience, 2020, 11, 830-839.	3.5	15
31	Probing the Manipulated Neurochemical Drive in Alcohol Addiction and Novel Therapeutic Advancements. ACS Chemical Neuroscience, 2020, 11, 1210-1217.	3.5	1
32	Sodium Channels: As an Eye of the Storm in Various Clinical Pathologies. , 2020, , 619-634.		3
33	Tetramethylpyrazine alleviates diabetic nephropathy through the activation of Akt signalling pathway in rats. European Journal of Pharmacology, 2019, 865, 172763.	3.5	22
34	Tetramethylpyrazine prevents diabetes by activating PI3K/Akt/GLUT-4 signalling in animal model of type-2 diabetes. Life Sciences, 2019, 236, 116836.	4.3	32
35	Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 167, 510-524.	5.5	76
36	Kinesins: Motor Proteins as Novel Target for the Treatment of Chronic Pain. Molecular Neurobiology, 2019, 56, 3854-3864.	4.0	11

#	Article	IF	CITATIONS
37	Kaempferol attenuates diabetic nephropathy by inhibiting RhoA/Rho-kinase mediated inflammatory signalling. Biomedicine and Pharmacotherapy, 2019, 109, 1610-1619.	5.6	88
38	Neuroprotective effects of silibinin: an <i>in silico</i> and <i>in vitro</i> study. International Journal of Neuroscience, 2018, 128, 935-945.	1.6	22
39	Cellular and molecular mechanisms driving neuropathic pain: recent advancements and challenges. Expert Opinion on Therapeutic Targets, 2018, 22, 131-142.	3.4	50
40	Peripherally Acting μ-Opioid Receptor Agonists Attenuate Ongoing Pain-associated Behavior and Spontaneous Neuronal Activity after Nerve Injury in Rats. Anesthesiology, 2018, 128, 1220-1236.	2.5	39
41	Astaxanthin ameliorates behavioral and biochemical alterations in in-vitro and in-vivo model of neuropathic pain. Neuroscience Letters, 2018, 674, 162-170.	2.1	55
42	Recent updates on GLP-1 agonists: Current advancements & challenges. Biomedicine and Pharmacotherapy, 2018, 108, 952-962.	5.6	157
43	Oligomerization of MrgC11 and μ-opioid receptors in sensory neurons enhances morphine analgesia. Science Signaling, 2018, 11, .	3.6	16
44	Targeting human Mas-related G protein-coupled receptor X1 to inhibit persistent pain. Proceedings of the United States of America, 2017, 114, E1996-E2005.	7.1	53
45	Diabetic nephropathy: New insights into established therapeutic paradigms and novel molecular targets. Diabetes Research and Clinical Practice, 2017, 128, 91-108.	2.8	118
46	Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches. Neuroscience and Biobehavioral Reviews, 2017, 83, 589-603.	6.1	47
47	Neuropathobiology of Alcohol-Induced Cognitive Deficits. , 2016, , 618-626.		0
48	Activation of cannabinoid CB1 receptor contributes to suppression of spinal nociceptive transmission and inhibition of mechanical hypersensitivity by Al²-fiber stimulation. Pain, 2016, 157, 2582-2593.	4.2	50
49	Activation of Peripheral μ-opioid Receptors by Dermorphin [<scp>d</scp> -Arg2, Lys4] (1–4) Amide Leads to Modality-preferred Inhibition of Neuropathic Pain. Anesthesiology, 2016, 124, 706-720.	2.5	40
50	Mas-Related G Protein-Coupled Receptors Offer Potential New Targets for Pain Therapy. Advances in Experimental Medicine and Biology, 2016, 904, 87-103.	1.6	18
51	Short-term pre- and post-Operative Stress Prolongs Incision-Induced Pain Hypersensitivity without Changing Basal Pain Perception. Molecular Pain, 2015, 11, s12990-015-0077.	2.1	37
52	Effects of Combined Electrical Stimulation of the Dorsal Column and Dorsal Roots on Wide-Dynamic-Range Neuronal Activity in Nerve-Injured Rats. Neuromodulation, 2015, 18, 592-598.	0.8	14
53	Electrical Stimulation of Dorsal Root Entry Zone Attenuates Wide-Dynamic-Range Neuronal Activity in Rats. Neuromodulation, 2015, 18, 33-40.	0.8	24
54	The inhibition of high-voltage-activated calcium current by activation of MrgC11 involves phospholipase C-dependent mechanisms. Neuroscience, 2015, 300, 393-403.	2.3	13

#	Article	IF	CITATIONS
55	Tmem100 Is a Regulator of TRPA1-TRPV1 Complex and Contributes to Persistent Pain. Neuron, 2015, 85, 833-846.	8.1	143
56	Selective keratinocyte stimulation is sufficient to evoke nociception in mice. Pain, 2015, 156, 656-665.	4.2	121
57	Electrical stimulation of low-threshold afferent fibers induces a prolonged synaptic depression in lamina II dorsal horn neurons to high-threshold afferent inputs in mice. Pain, 2015, 156, 1008-1017.	4.2	63
58	Comparison of intensityâ€dependent inhibition of spinal wideâ€dynamic range neurons by dorsal column and peripheral nerve stimulation in a rat model of neuropathic pain. European Journal of Pain, 2014, 18, 978-988.	2.8	46
59	Temporal changes in MrgC expression after spinal nerve injury. Neuroscience, 2014, 261, 43-51.	2.3	24
60	Impaired Neuropathic Pain and Preserved Acute Pain in Rats Overexpressing Voltage-Gated Potassium Channel Subunit Kv1.2 in Primary Afferent Neurons. Molecular Pain, 2014, 10, 1744-8069-10-8.	2.1	77
61	Modulating the delicate glial–neuronal interactions in neuropathic pain: Promises and potential caveats. Neuroscience and Biobehavioral Reviews, 2014, 45, 19-27.	6.1	74
62	MrgC agonism at central terminals of primary sensory neurons inhibits neuropathic pain. Pain, 2014, 155, 534-544.	4.2	38
63	Suppression of spinal connexin 43 expression attenuates mechanical hypersensitivity in rats after an L5 spinal nerve injury. Neuroscience Letters, 2014, 566, 194-199.	2.1	33
64	Intrathecal carbenoxolone inhibits neuropathic pain and spinal wide-dynamic range neuronal activity in rats after an L5 spinal nerve injury. Neuroscience Letters, 2014, 563, 45-50.	2.1	19
65	Activation of MrgC receptor inhibits N-type calcium channels in small-diameter primary sensory neurons in mice. Pain, 2014, 155, 1613-1621.	4.2	24
66	Opioid receptor–triggered spinal mTORC1 activation contributes to morphine tolerance and hyperalgesia. Journal of Clinical Investigation, 2014, 124, 592-603.	8.2	142
67	Resveratrol abrogates alcohol-induced cognitive deficits by attenuating oxidative–nitrosative stress and inflammatory cascade in the adult rat brain. Neurochemistry International, 2013, 62, 861-869.	3.8	73
68	A long noncoding RNA contributes to neuropathic pain by silencing Kcna2 in primary afferent neurons. Nature Neuroscience, 2013, 16, 1024-1031.	14.8	319
69	Protective effect of curcumin against chronic alcohol-induced cognitive deficits and neuroinflammation in the adult rat brain. Neuroscience, 2013, 244, 147-158.	2.3	58
70	Tocotrienol and Cognitive Dysfunction Induced by Alcohol. , 2013, , 181-202.		2
71	Attenuation of NF-κβ mediated apoptotic signaling by tocotrienol ameliorates cognitive deficits in rats postnatally exposed to ethanol. Neurochemistry International, 2012, 61, 310-320.	3.8	18
72	Attenuation of oxidative stress, neuroinflammation, and apoptosis by curcumin prevents cognitive deficits in rats postnatally exposed to ethanol. Psychopharmacology, 2012, 224, 519-535.	3.1	61

#	Article	IF	CITATIONS
73	Neuroprotective Effect of Vitamin E Isoforms Against Chronic Alcoholâ€induced Peripheral Neurotoxicity: Possible Involvement of Oxidativeâ€Nitrodative Stress. Phytotherapy Research, 2012, 26, 1738-1745.	5.8	17
74	Alcoholic neuropathy: possible mechanisms and future treatment possibilities. British Journal of Clinical Pharmacology, 2012, 73, 348-362.	2.4	178
75	Resveratrol prevents alcohol-induced cognitive deficits and brain damage by blocking inflammatory signaling and cell death cascade in neonatal rat brain. Journal of Neurochemistry, 2011, 117, no-no.	3.9	78
76	Curcumin ameliorates reserpine-induced pain–depression dyad: Behavioural, biochemical, neurochemical and molecular evidences. Psychoneuroendocrinology, 2011, 36, 1570-1581.	2.7	114
77	Modulation of nitrergic pathway by sesamol prevents cognitive deficits and associated biochemical alterations in intracerebroventricular streptozotocin administered rats. European Journal of Pharmacology, 2011, 659, 177-186.	3.5	36
78	<i>Emblica officinalis</i> Corrects Functional, Biochemical and Molecular Deficits in Experimental Diabetic Neuropathy by Targeting the Oxidoâ€nitrosative Stress Mediated Inflammatory Cascade. Phytotherapy Research, 2011, 25, 1527-1536.	5.8	59
79	Amelioration of functional, biochemical and molecular deficits by epigallocatechin gallate in experimental model of alcoholic neuropathy. European Journal of Pain, 2011, 15, 286-292.	2.8	24
80	Protective Effect of Epigallocatechin Gallate in Murine Waterâ€Immersion Stress Model of Chronic Fatigue Syndrome. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 490-496.	2.5	27
81	Epigallocatechin-3-gallate ameliorates alcohol-induced cognitive dysfunctions and apoptotic neurodegeneration in the developing rat brain. International Journal of Neuropsychopharmacology, 2010, 13, 1053-1066.	2.1	26
82	Sesamol Suppresses Neuro-Inflammatory Cascade in Experimental Model of Diabetic Neuropathy. Journal of Pain, 2010, 11, 950-957.	1.4	71
83	Tocotrienol ameliorates behavioral and biochemical alterations in the rat model of alcoholic neuropathy. Pain, 2009, 145, 129-135.	4.2	40
84	Suppression of NF-Î ^e β signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Pharmacology Biochemistry and Behavior, 2009, 92, 251-259.	2.9	149
85	Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative–nitrosative stress in rats. Pharmacology Biochemistry and Behavior, 2009, 93, 183-189.	2.9	132
86	Suppression of neuro-inflammatory signaling cascade by tocotrienol can prevent chronic alcohol-induced cognitive dysfunction in rats. Behavioural Brain Research, 2009, 203, 296-303.	2.2	85
87	Epigallocatechin gallate ameliorates chronic fatigue syndrome in mice: Behavioral and biochemical evidence. Behavioural Brain Research, 2009, 205, 414-420.	2.2	21